CLOs on the Move

ITC Nexus Dx

www.itcmed.com

 
ITC is a wholly-owned subsidiary of Thoratec and develops, manufactures and markets medical devices used in three distinct segments of the medical field.
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.itcmed.com
  • 8 Olsen Ave
    Edison, NJ USA 08820-2419
  • Phone: 732.548.5700

Executives

Name Title Contact Details

Similar Companies

Burgess Health Center

Burgess Health Center is committed to improve the quality of life for the people and communities we serve by providing excellent healthcare and exceptional patient experiences.

Eye Health Northwest

Eye Health Northwest is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Richman Root Delaney MD

Richman Root Delaney MD is a Waterford, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Highmark Blue Cross Blue Shield West Virginia

Highmark Blue Cross Blue Shield West Virginia is a Parkersburg, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Uroplasty

Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Female SUI only in U.S.; male and female SUI outside the U.S. Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.